vs

Side-by-side financial comparison of LEXICON PHARMACEUTICALS, INC. (LXRX) and AIRWA INC. (YYAI). Click either name above to swap in a different company.

LEXICON PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($5.5M vs $3.0M, roughly 1.8× AIRWA INC.). AIRWA INC. runs the higher net margin — -7.4% vs -282.7%, a 275.3% gap on every dollar of revenue. On growth, AIRWA INC. posted the faster year-over-year revenue change (729.8% vs 254.4%). Over the past eight quarters, LEXICON PHARMACEUTICALS, INC.'s revenue compounded faster (124.2% CAGR vs 14.3%).

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 1...

Flying W Airways (FWA) was a briefly high-profile publicly-traded company of the late 1960s/early 1970s, which originated in 1961 when its founders opened Flying W Airport in New Jersey as a fly-in resort. FWA became a bet on Alaskan oil and at its peak in 1969 attracted investment by the Matlack family, had two Hollywood actors on its board and bought Red Dodge Aviation (RDA) of Alaska, for which it acquired Lockheed L-100 Hercules aircraft, to take advantage of forthcoming Alaska pipeline c...

LXRX vs YYAI — Head-to-Head

Bigger by revenue
LXRX
LXRX
1.8× larger
LXRX
$5.5M
$3.0M
YYAI
Growing faster (revenue YoY)
YYAI
YYAI
+475.4% gap
YYAI
729.8%
254.4%
LXRX
Higher net margin
YYAI
YYAI
275.3% more per $
YYAI
-7.4%
-282.7%
LXRX
Faster 2-yr revenue CAGR
LXRX
LXRX
Annualised
LXRX
124.2%
14.3%
YYAI

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
LXRX
LXRX
YYAI
YYAI
Revenue
$5.5M
$3.0M
Net Profit
$-15.5M
$-221.8K
Gross Margin
96.3%
75.2%
Operating Margin
-269.1%
1.8%
Net Margin
-282.7%
-7.4%
Revenue YoY
254.4%
729.8%
Net Profit YoY
54.0%
83.8%
EPS (diluted)
$-0.04
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LXRX
LXRX
YYAI
YYAI
Q4 25
$5.5M
$3.0M
Q3 25
$14.2M
$3.0M
Q2 25
$28.9M
$3.0M
Q1 25
$1.3M
$3.3M
Q4 24
$1.6M
$3.3M
Q3 24
$1.7M
$3.3M
Q2 24
$1.6M
$-701.1K
Q1 24
$1.1M
Net Profit
LXRX
LXRX
YYAI
YYAI
Q4 25
$-15.5M
$-221.8K
Q3 25
$-12.8M
$1.3M
Q2 25
$3.3M
$552.2K
Q1 25
$-25.3M
$-411.2K
Q4 24
$-1.4M
Q3 24
$-64.8M
$-4.2M
Q2 24
$-53.4M
Q1 24
$-48.4M
Gross Margin
LXRX
LXRX
YYAI
YYAI
Q4 25
96.3%
75.2%
Q3 25
99.9%
75.2%
Q2 25
99.9%
75.2%
Q1 25
97.6%
77.3%
Q4 24
77.5%
77.3%
Q3 24
95.9%
77.3%
Q2 24
89.7%
Q1 24
97.2%
Operating Margin
LXRX
LXRX
YYAI
YYAI
Q4 25
-269.1%
1.8%
Q3 25
-85.9%
49.7%
Q2 25
12.9%
42.7%
Q1 25
-2034.8%
16.2%
Q4 24
71.2%
Q3 24
-3658.4%
74.6%
Q2 24
-3423.3%
Q1 24
-4147.6%
Net Margin
LXRX
LXRX
YYAI
YYAI
Q4 25
-282.7%
-7.4%
Q3 25
-90.0%
42.0%
Q2 25
11.3%
18.4%
Q1 25
-2004.4%
-12.6%
Q4 24
-41.7%
Q3 24
-3722.6%
-129.0%
Q2 24
-3304.2%
Q1 24
-4427.9%
EPS (diluted)
LXRX
LXRX
YYAI
YYAI
Q4 25
$-0.04
$-0.05
Q3 25
$-0.04
Q2 25
$0.01
Q1 25
$-0.07
$-1.41
Q4 24
$6.43
Q3 24
$-0.18
$-1.91
Q2 24
$-0.17
$-30.98
Q1 24
$-0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LXRX
LXRX
YYAI
YYAI
Cash + ST InvestmentsLiquidity on hand
$96.2M
$107.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$107.5M
$165.4M
Total Assets
$185.0M
$172.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LXRX
LXRX
YYAI
YYAI
Q4 25
$96.2M
$107.0M
Q3 25
$116.0M
$2.5M
Q2 25
$139.0M
$1.4M
Q1 25
$194.8M
$4.3M
Q4 24
$238.0M
$18.1M
Q3 24
$258.4M
$18.2M
Q2 24
$310.0M
$1.8M
Q1 24
$355.6M
Stockholders' Equity
LXRX
LXRX
YYAI
YYAI
Q4 25
$107.5M
$165.4M
Q3 25
$120.2M
$26.2M
Q2 25
$129.4M
$25.3M
Q1 25
$123.0M
$26.1M
Q4 24
$145.9M
$8.0M
Q3 24
$178.5M
$9.4M
Q2 24
$240.0M
$9.6M
Q1 24
$288.9M
Total Assets
LXRX
LXRX
YYAI
YYAI
Q4 25
$185.0M
$172.1M
Q3 25
$205.9M
$34.7M
Q2 25
$225.6M
$32.9M
Q1 25
$297.7M
$30.7M
Q4 24
$298.4M
$21.6M
Q3 24
$321.1M
$23.2M
Q2 24
$373.4M
$23.2M
Q1 24
$417.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LXRX
LXRX
YYAI
YYAI
Operating Cash FlowLast quarter
$-17.2M
$-30.8M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LXRX
LXRX
YYAI
YYAI
Q4 25
$-17.2M
$-30.8M
Q3 25
$-23.8M
$-1.1M
Q2 25
$17.0M
$-423.7K
Q1 25
$-43.8M
$-133.8K
Q4 24
$-178.8M
$779.4K
Q3 24
$-53.6M
$-601.3K
Q2 24
$-48.5M
$-460.3K
Q1 24
$-55.1M
Free Cash Flow
LXRX
LXRX
YYAI
YYAI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$-179.8M
Q3 24
$-53.9M
Q2 24
$-48.8M
Q1 24
FCF Margin
LXRX
LXRX
YYAI
YYAI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-11600.7%
Q3 24
-3097.4%
Q2 24
-3017.3%
Q1 24
Capex Intensity
LXRX
LXRX
YYAI
YYAI
Q4 25
Q3 25
0.0%
Q2 25
Q1 25
Q4 24
66.5%
Q3 24
17.6%
Q2 24
15.5%
Q1 24
0.0%
Cash Conversion
LXRX
LXRX
YYAI
YYAI
Q4 25
Q3 25
-0.86×
Q2 25
5.23×
-0.77×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons